WuXi Juno: Revenue is expected to increase by 79.3% to 284 million yuan by 2025, with gross profit growth benefiting from the licensing contribution of sLVV and sales growth of core products.

Recently, WuXi AppTec announced its performance for the year ending December 31, 2025. The company’s revenue was 284 million yuan, an increase of 79.3% compared to 2024. This revenue primarily came from the sales of Benauda® and the non-exclusive licensing of production processes and related technologies granted to Juno. Product sales revenue was 219 million yuan, a year-on-year increase of 38.4%. Gross profit rose from 77.3 million yuan to 173 million yuan, an increase of 123.9%, with the gross margin increasing from 48.9% to 50.9%. The increase in gross profit was mainly attributed to the contribution of sLVV licensing and the growth in Benauda® sales.

In terms of selling expenses, the company spent 154 million yuan in 2025, accounting for 70.5% of product revenue, a decrease from 88.7% in 2024, indicating improved sales efficiency. General and administrative expenses significantly decreased by 34.6% to 78.5 million yuan, mainly due to organizational streamlining and cost control. R&D expenses also decreased to 188 million yuan, down 33.4%, primarily due to improved operational efficiency and progress in clinical trials.

In the notes to the financial statements, other income and losses increased from 148 million yuan to 319 million yuan, mainly due to an increase in impairment losses on intangible assets of 223 million yuan, partially offset by foreign exchange gains. The annual loss was 555 million yuan, a decrease compared to last year.

Overall, the company’s core product Benauda® continues to make market progress in the field of cell immunotherapy, and the R&D pipeline is also steadily advancing.

(WuXi AppTec Announcement)

(Edited by: Yang Yan Lin Chen)

Keywords:
Medical